Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Melanoma 273Carcinoma, Non-Small-Cell Lung 244Carcinoma, Renal Cell 144Neoplasms 99Neoplasm Metastasis 99Squamous Cell Carcinoma of Head and Neck 88Carcinoma, Hepatocellular 87Colorectal Neoplasms 82Lung Neoplasms 77Stomach Neoplasms 59Pancreatic Neoplasms 56Carcinoma, Transitional Cell 50Hodgkin Disease 47Urinary Bladder Neoplasms 42Head and Neck Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Brain Neoplasms 33Sarcoma 32Prostatic Neoplasms 32Glioblastoma 32Kidney Neoplasms 29Recurrence 28Multiple Myeloma 25Esophageal Neoplasms 24Uveal Melanoma 23Skin Neoplasms 23Uterine Cervical Neoplasms 22

Interventions

Cyclophosphamide 9Pemetrexed 6pembrolizumab 5fludarabine 5Gemcitabine 5Cisplatin 5Carboplatin 5ponatinib 4atezolizumab 4Rituximab 4Dexamethasone 4Bevacizumab 4130-nm albumin-bound paclitaxel 4Sunitinib 3Melphalan 3Lutetium 3Doxorubicin 3Bortezomib 3tetulomab tetraxetan lu-177 2pralsetinib 2pomalidomide 2osimertinib 2napabucasin 2isatuximab 2fludarabine phosphate 2ficlatuzumab 2entrectinib 2entinostat 2durvalumab 2cobimetinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × Nivolumab × Clear all
NCT06463665 2026-06-04

VIRO-25

Genelux Corporation

Phase 2 Recruiting
142 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT04572451 2025-08-01

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

University of Pittsburgh

Phase 1 Recruiting
50 enrolled
Dermatologic

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡